Form 4: Enliven Therapeutics CEO Granted 875,000 Stock Options

Enliven Therapeutics' President and CEO, Richard A. Fair, was granted 875,000 stock options with an exercise price of $18.77, vesting over several years.

Summary

• Richard A. Fair, President and CEO, and a Director of Enliven Therapeutics, Inc. (ELVN), acquired 875,000 derivative securities in the form of stock options.
• The transaction date for this grant was December 11, 2025.
• The exercise price for these stock options is $18.77 per share.
• The options will begin vesting on December 11, 2026, with 1/4th of the shares vesting on that date.
• Following the initial vesting, 1/48th of the shares subject to the option will vest each month thereafter.
• Vesting is contingent upon Mr. Fair continuing as a service provider to the company through each vesting date.
• The expiration date for these stock options is December 11, 2035.
• The options represent the right to buy 875,000 shares of Enliven Therapeutics' Common Stock.
• Following this reported transaction, Mr. Fair beneficially owns 875,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of significant stock options to the CEO is generally a positive signal, indicating management's long-term commitment and alignment with shareholder interests. It's a standard compensation practice, not directly indicative of immediate financial performance, but reflects confidence in future growth.

Positives

• The grant of a significant number of stock options to the President and CEO aligns management's long-term interests with those of shareholders, incentivizing performance and stock price appreciation.
• The long vesting schedule (over four years) demonstrates a commitment from the CEO to the company's sustained future success.

Future Outlook

The vesting schedule for the stock options, extending over several years, indicates an expectation of continued service from the President and CEO, Richard A. Fair, and ties his future compensation directly to the company's long-term performance.

Industry Context

The grant of stock options to a CEO is a standard practice in the biotechnology and pharmaceutical industries, as well as across many public companies, to attract, retain, and incentivize executive talent by linking their compensation to shareholder value creation.

Comparison to Industry Standards

• Executive equity grants, such as stock options, are a common component of compensation packages for CEOs in publicly traded companies, aligning their financial interests with company performance.
• The vesting schedule, with an initial cliff followed by monthly vesting, is a typical structure designed to encourage long-term commitment and retention, comparable to practices at companies like Moderna or Pfizer for their executive teams.

Related Party Transactions

• The transaction involves the grant of stock options to Richard A. Fair, the President and CEO and a Director of Enliven Therapeutics, Inc., which is a standard form of executive compensation and an insider transaction.

Stakeholder Impact

• Shareholders: The grant aligns the CEO's financial incentives with shareholder value creation, potentially leading to more focused efforts on increasing the company's stock price.
• Employees: May signal stability in leadership and a long-term vision for the company.
• Creditors: No direct impact, but a well-incentivized management team can contribute to long-term financial health.

Next Steps

• The stock options will begin to vest on December 11, 2026, with subsequent monthly vesting periods.

Key Dates

Keywords

Enliven Therapeutics, ELVN, stock options, executive compensation, insider transaction, Form 4, Richard A. Fair, CEO, equity grant